Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 615

1.

Ureteral wall volume at ureteral stone site is a critical predictor for shock wave lithotripsy outcomes: comparison with ureteral wall thickness and area.

Yamashita S, Kohjimoto Y, Iguchi T, Nishizawa S, Kikkawa K, Hara I.

Urolithiasis. 2019 Aug 23. doi: 10.1007/s00240-019-01154-w. [Epub ahead of print]

PMID:
31444520
2.

Postoperative Progress after Stone Removal Following Treatment for Obstructive Acute Pyelonephritis Associated with Urinary Tract Calculi: A Retrospective Study.

Yamashita S, Kohjimoto Y, Higuchi M, Ueda Y, Iguchi T, Hara I.

Urol J. 2019 Jul 22. doi: 10.22037/uj.v0i0.4847. [Epub ahead of print]

3.

Robotic total gastrectomy with Roux-en-Y reconstruction for gastric cancer (with video).

Ojima T, Hara I, Yamaue H.

J Visc Surg. 2019 Oct;156(5):461-462. doi: 10.1016/j.jviscsurg.2019.06.004. Epub 2019 Jul 10. No abstract available.

PMID:
31302014
4.

Photoacoustic diagnosis of pharmacokinetics and vascular shutdown effects in photodynamic treatment with indocyanine green-lactosome for a subcutaneous tumor in mice.

Tsunoi Y, Araki K, Ozeki E, Hara I, Shiotani A, Terakawa M, Sato S.

Photodiagnosis Photodyn Ther. 2019 Jun;26:436-441. doi: 10.1016/j.pdpdt.2019.04.031. Epub 2019 May 1.

PMID:
31054334
5.

The association of length of the resected membranous urethra with urinary incontinence after radical prostatectomy.

Kohjimoto Y, Yamashita S, Kikkawa K, Iba A, Matsumura N, Hara I.

Urol J. 2019 Mar 18. doi: 10.22037/uj.v0i0.4753. [Epub ahead of print]

6.

Noncontrast Computed Tomography Parameters for Predicting Shock Wave Lithotripsy Outcome in Upper Urinary Tract Stone Cases.

Yamashita S, Kohjimoto Y, Iwahashi Y, Iguchi T, Nishizawa S, Kikkawa K, Hara I.

Biomed Res Int. 2018 Dec 2;2018:9253952. doi: 10.1155/2018/9253952. eCollection 2018. Review.

7.

Aggressive TFEB-rearranged renal cell carcinoma mimicking chromophobe and clear cell renal cell carcinoma.

Kojima F, Kuroda N, Matsuzaki I, Miyai H, Hara I, Murata SI, Hes O.

Pathol Int. 2019 Jan;69(1):51-53. doi: 10.1111/pin.12744. Epub 2019 Jan 8. No abstract available.

PMID:
30620430
8.

Three-dimensional mean stone density measurement is superior for predicting extracorporeal shock wave lithotripsy success.

Yamashita S, Kohjimoto Y, Iwahashi Y, Iguchi T, Iba A, Nishizawa S, Hara I.

Int J Urol. 2019 Feb;26(2):185-191. doi: 10.1111/iju.13827. Epub 2018 Oct 17.

PMID:
30332713
9.

[A Case of Giant Testicular Tumor with Pelvic and Inguinal Lymph Nodes Metastasis].

Iguchi T, Yamashita S, Nishizawa S, Iba A, Kohjimoto Y, Hara I.

Hinyokika Kiyo. 2018 Jun;64(6):277-281. doi: 10.14989/ActaUrolJap_64_6_277. Japanese.

10.

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial.

Hara I, Yamashita S, Nishizawa S, Kikkawa K, Shimokawa T, Kohjimoto Y.

JMIR Res Protoc. 2018 Jul 27;7(7):e11191. doi: 10.2196/11191.

11.

Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer.

Obara W, Hara I, Kato Y, Kato R, Inoue K, Sato F, Mimata H, Nakamura Y, Fujioka T.

Cancer Immunol Immunother. 2018 Sep;67(9):1371-1380. doi: 10.1007/s00262-018-2197-x. Epub 2018 Jul 3.

PMID:
29971464
12.

Loss of SWI/SNF complex expression in undifferentiated renal carcinoma in acquired cystic kidney.

Kojima F, Ueda Y, Matsuzaki I, Hara I, Murata SI.

Pathol Int. 2018 Apr 19. doi: 10.1111/pin.12671. [Epub ahead of print] No abstract available.

PMID:
29671925
13.

Recurrent stone-forming patients have high visceral fat ratio based on computed tomography images compared to first-time stone-forming patients.

Yamashita S, Iguchi T, Nishizawa S, Iba A, Kohjimoto Y, Hara I.

Int J Urol. 2018 Jun;25(6):569-573. doi: 10.1111/iju.13564. Epub 2018 Apr 12.

14.

Distinct interactions of Sox5 and Sox10 in fate specification of pigment cells in medaka and zebrafish.

Nagao Y, Takada H, Miyadai M, Adachi T, Seki R, Kamei Y, Hara I, Taniguchi Y, Naruse K, Hibi M, Kelsh RN, Hashimoto H.

PLoS Genet. 2018 Apr 5;14(4):e1007260. doi: 10.1371/journal.pgen.1007260. eCollection 2018 Apr.

15.

Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.

Kikkawa K, Iba A, Kohjimoto Y, Noda Y, Sonomura T, Hara I.

Int J Urol. 2018 Apr;25(4):366-371. doi: 10.1111/iju.13530. Epub 2018 Feb 4.

16.

Polymeric Micelle of A₃B-Type Lactosome as a Vehicle for Targeting Meningeal Dissemination.

Kurihara K, Ueda M, Hara I, Ozeki E, Togashi K, Kimura S.

Nanomaterials (Basel). 2018 Jan 31;8(2). pii: E79. doi: 10.3390/nano8020079.

17.

Cellular stress induces cancer stem-like cells through expression of DNAJB8 by activation of heat shock factor 1.

Kusumoto H, Hirohashi Y, Nishizawa S, Yamashita M, Yasuda K, Murai A, Takaya A, Mori T, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Kondo T, Sato N, Hara I, Torigoe T.

Cancer Sci. 2018 Mar;109(3):741-750. doi: 10.1111/cas.13501. Epub 2018 Feb 20.

18.

cGAS drives noncanonical-inflammasome activation in age-related macular degeneration.

Kerur N, Fukuda S, Banerjee D, Kim Y, Fu D, Apicella I, Varshney A, Yasuma R, Fowler BJ, Baghdasaryan E, Marion KM, Huang X, Yasuma T, Hirano Y, Serbulea V, Ambati M, Ambati VL, Kajiwara Y, Ambati K, Hirahara S, Bastos-Carvalho A, Ogura Y, Terasaki H, Oshika T, Kim KB, Hinton DR, Leitinger N, Cambier JC, Buxbaum JD, Kenney MC, Jazwinski SM, Nagai H, Hara I, West AP, Fitzgerald KA, Sadda SR, Gelfand BD, Ambati J.

Nat Med. 2018 Jan;24(1):50-61. doi: 10.1038/nm.4450. Epub 2017 Nov 27.

19.

Necrotizing fasciitis after high-dose rate brachytherapy and external beam radiation for prostate cancer: a case report.

Yamashita S, Kohjimoto Y, Iba A, Kikkawa K, Hara I.

BMC Urol. 2017 Nov 21;17(1):107. doi: 10.1186/s12894-017-0299-y.

20.

Upper urinary tract stone disease in patients with poor performance status: active stone removal or conservative management?

Yamashita S, Kohjimoto Y, Hirabayashi Y, Iguchi T, Iba A, Higuchi M, Koike H, Wakamiya T, Nishizawa S, Hara I.

BMC Urol. 2017 Nov 16;17(1):103. doi: 10.1186/s12894-017-0293-4.

21.

Modulation of immunogenicity of poly(sarcosine) displayed on various nanoparticle surfaces due to different physical properties.

Kim CJ, Hara E, Watabe N, Hara I, Kimura S.

J Pept Sci. 2017 Dec;23(12):889-898. doi: 10.1002/psc.3053. Epub 2017 Nov 7.

PMID:
29110375
22.

Identification of antigenic peptides from novel renal cancer stem-like cell antigen, DNAJB8.

Nishizawa S, Hirohashi Y, Kusumoto H, Wakamiya T, Iguchi T, Yamashita S, Iba A, Kikkawa K, Kohjimoto Y, Torigoe T, Hara I.

Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):693-699. doi: 10.1016/j.bbrc.2017.10.146. Epub 2017 Oct 28.

PMID:
29107688
23.

Molecular diagnosis of lymph node metastasis in patients with upper urinary tract cancer who underwent lymphadenectomy.

Kodama Y, Kondo T, Matsumura N, Shimokawa T, Kohjimoto Y, Tanabe K, Hara I.

Int J Urol. 2017 Nov;24(11):799-806. doi: 10.1111/iju.13429. Epub 2017 Oct 12.

24.

Near-infrared fluorescence imaging and photodynamic therapy with indocyanine green lactosome has antineoplastic effects for hepatocellular carcinoma.

Tsuda T, Kaibori M, Hishikawa H, Nakatake R, Okumura T, Ozeki E, Hara I, Morimoto Y, Yoshii K, Kon M.

PLoS One. 2017 Aug 31;12(8):e0183527. doi: 10.1371/journal.pone.0183527. eCollection 2017.

25.

Stone size is a predictor for residual stone and multiple procedures of endoscopic combined intrarenal surgery.

Yamashita S, Kohjimoto Y, Iba A, Kikkawa K, Hara I.

Scand J Urol. 2017 Apr;51(2):159-164. doi: 10.1080/21681805.2017.1284897. Epub 2017 Feb 13.

PMID:
28635566
26.
27.

A fact and problems of the anticancer chemotherapy for elderly patients.

Hara I.

Nihon Rinsho. 2017 Apr;75(4):626-630. Japanese.

PMID:
30549870
28.

Macrocystic ductal adenocarcinoma of prostate: A rare gross appearance of prostate cancer.

Kojima F, Koike H, Matsuzaki I, Iwahashi Y, Warigaya K, Fujimoto M, Ono K, Urata Y, Kohjimoto Y, Hara I, Murata SI.

Ann Diagn Pathol. 2017 Apr;27:7-13. doi: 10.1016/j.anndiagpath.2016.12.002. Epub 2016 Dec 29.

PMID:
28325365
29.

Health-related quality of life after robot-assisted radical prostatectomy compared with laparoscopic radical prostatectomy.

Koike H, Kohjimoto Y, Iba A, Kikkawa K, Yamashita S, Iguchi T, Matsumura N, Hara I.

J Robot Surg. 2017 Sep;11(3):325-331. doi: 10.1007/s11701-016-0659-8. Epub 2017 Jan 27.

PMID:
28130703
30.

Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.

Matsumura N, Nakamura Y, Kohjimoto Y, Nishizawa S, Kikkawa K, Iba A, Kodama Y, Hara I.

Int J Urol. 2017 Mar;24(3):230-235. doi: 10.1111/iju.13274. Epub 2017 Jan 9.

31.

Variation Coefficient of Stone Density: A Novel Predictor of the Outcome of Extracorporeal Shockwave Lithotripsy.

Yamashita S, Kohjimoto Y, Iguchi T, Nishizawa S, Iba A, Kikkawa K, Hara I.

J Endourol. 2017 Apr;31(4):384-390. doi: 10.1089/end.2016.0719. Epub 2017 Feb 2.

PMID:
28052698
32.

[GIANT CELL CARCINOMA OF THE RENAL PELVIS AND URETER WITH GIANT HYDRONEPHROSIS; A CASE REPORT].

Wakamiya T, Matsumura N, Kodama Y, Kohjimoto Y, Hara I.

Nihon Hinyokika Gakkai Zasshi. 2017;108(4):200-203. doi: 10.5980/jpnjurol.108.200. Japanese.

33.

A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.

Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, Minami K, Enomoto Y, Nasu T, Yoshida T, Fuse H, Hara I, Kawaguchi K, Arimura A, Fujioka T.

Ann Oncol. 2017 Apr 1;28(4):798-803. doi: 10.1093/annonc/mdw675.

PMID:
27998971
34.

Reduced immune response to polymeric micelles coating sialic acids.

Ohmae M, Kojima M, Mihara K, Yamazaki Y, Hara I, Hara E, Kimura S.

Bioorg Med Chem Lett. 2016 Oct 15;26(20):4976-4982. doi: 10.1016/j.bmcl.2016.09.004. Epub 2016 Sep 4.

PMID:
27624073
35.

Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer.

Kondo T, Hara I, Takagi T, Kodama Y, Hashimoto Y, Kobayashi H, Iizuka J, Omae K, Yoshida K, Tanabe K.

Int J Clin Oncol. 2017 Feb;22(1):145-152. doi: 10.1007/s10147-016-1024-7. Epub 2016 Jul 23.

PMID:
27450420
36.

[Significance of clinical guideline and general rule for clinical and pathological studies].

Hara I.

Nihon Rinsho. 2016 May 20;74 Suppl 3:251-5. Japanese. No abstract available.

PMID:
27344737
37.

Near-infrared fluorescence imaging with indocyanine green-lactosomes in a mouse model of rheumatoid arthritis.

Onishi S, Sakane M, Tsukanishi T, Funayama T, Ozeki E, Hara I, Yamazaki M.

Mod Rheumatol. 2016 Nov;26(6):885-890. doi: 10.3109/14397595.2016.1170946. Epub 2016 May 4.

PMID:
27141810
38.

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.

Yamashita S, Kohjimoto Y, Iguchi T, Koike H, Kusumoto H, Iba A, Kikkawa K, Kodama Y, Matsumura N, Hara I.

BMC Urol. 2016 Mar 22;16:13. doi: 10.1186/s12894-016-0133-y.

39.

Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.

Low SK, Fukunaga K, Takahashi A, Matsuda K, Hongo F, Nakanishi H, Kitamura H, Inoue T, Kato Y, Tomita Y, Fukasawa S, Tanaka T, Nishimura K, Uemura H, Hara I, Fujisawa M, Matsuyama H, Hashine K, Tatsugami K, Enokida H, Kubo M, Miki T, Mushiroda T.

PLoS One. 2016 Feb 25;11(2):e0148177. doi: 10.1371/journal.pone.0148177. eCollection 2016.

40.

Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association.

Koie T, Ohyama C, Fujimoto H, Nishiyama H, Miyazaki J, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T; Cancer Registration Committee of the Japanese Urological Association, Ohyama C, Nishiyama H, Fujisawa M, Uemura H, Fujimoto H, Suzuki K, Eto M, Hara I, Matsubara A, Nonomura N, Nakanishi H, Koie T, Kanayama H, Miki T, Fukumori T, Naito S; Cancer Registration Committee of the Japanese Urological Association.

Jpn J Clin Oncol. 2016 May;46(5):468-74. doi: 10.1093/jjco/hyw005. Epub 2016 Feb 6.

PMID:
26851754
41.

[Recent advances in diagnosis of prostate cancer].

Hara I.

Nihon Rinsho. 2016 Jan;74(1):20-4. Japanese.

PMID:
26793874
42.

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients - A propensity scoring approach.

Nagao K, Matsuyama H, Nozawa M, Hara I, Nishioka T, Komura T, Esa A, Uejima S, Imanishi M, Uekado Y, Ogawa T, Kajikawa H, Uemura H.

Asian J Urol. 2016 Jan;3(1):33-38. doi: 10.1016/j.ajur.2015.10.003. Epub 2015 Oct 31.

43.

Transplantation of Horseshoe Kidney from Living, Genetically Unrelated Donor.

Kikkawa K, Wakamiya T, Kusumoto H, Matsumura N, Kohjimoto Y, Hara I.

Case Rep Transplant. 2015;2015:390381. doi: 10.1155/2015/390381. Epub 2015 Jul 9.

44.

Theranostic Photosensitive Nanoparticles for Lymph Node Metastasis of Gastric Cancer.

Tsujimoto H, Morimoto Y, Takahata R, Nomura S, Yoshida K, Hiraki S, Horiguchi H, Miyazaki H, Ono S, Saito D, Hara I, Ozeki E, Yamamoto J, Hase K.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S923-8. doi: 10.1245/s10434-015-4594-0. Epub 2015 May 19.

PMID:
25986868
45.

Naftopidil versus flopropione as medical expulsive therapy for distal ureteral stones: results of a randomized, multicenter, double-blind, controlled trial.

Kohjimoto Y, Hagino K, Ogawa T, Inagaki T, Kitamura S, Nishihata M, Iba A, Matsumura N, Hara I.

World J Urol. 2015 Dec;33(12):2125-9. doi: 10.1007/s00345-015-1556-x. Epub 2015 Apr 14.

PMID:
25869815
46.

[The effect of self-training in advance using an e-learning system on pharmacological practice].

Hara I, Suzuki H, Kusakari S, Matsuoka M.

Nihon Yakurigaku Zasshi. 2015 Feb;145(2):80-4. doi: 10.1254/fpj.145.80. Japanese. No abstract available.

PMID:
25747019
47.

Weight loss intervention reduces the risk of kidney stone formation in a rat model of metabolic syndrome.

Sasaki Y, Kohjimoto Y, Iba A, Matsumura N, Hara I.

Int J Urol. 2015 Apr;22(4):404-9. doi: 10.1111/iju.12691. Epub 2015 Jan 13.

48.

Robot-assisted surgical approach to bladder cancer: a decade of progress!

Al-Tartir T, Raza S, Alotaibi M, Khan A, Hara I, Fujisawa M, Guru K.

Minerva Urol Nefrol. 2015 Mar;67(1):55-63. Epub 2014 Nov 11. Review.

PMID:
25386697
49.

Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.

Nozawa M, Hara I, Matsuyama H, Iki M, Nagao K, Nishioka T, Komura T, Esa A, Uejima S, Imanishi M, Uekado Y, Ogawa T, Kajikawa H, Uemura H.

World J Urol. 2015 Sep;33(9):1263-8. doi: 10.1007/s00345-014-1431-1. Epub 2014 Oct 30.

PMID:
25354720
50.

Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.

Nishizawa S, Inagaki T, Iba A, Kikkawa K, Kodama Y, Matsumura N, Kohjimoto Y, Hara I.

Springerplus. 2014 Oct 8;3:586. doi: 10.1186/2193-1801-3-586. eCollection 2014.

Supplemental Content

Support Center